Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Sell
35
STOK Quote, Financials, Valuation and Earnings
Last price:
$8.15
Seasonality move
:
19.76%
Day range:
$8.00 - $8.42
52-week range:
$5.80 - $17.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.27x
P/B ratio:
1.97x
Volume:
1.1M
Avg. volume:
793.9K
1-year change:
39.07%
Market cap:
$450.5M
Revenue:
$36.6M
EPS (TTM):
-$1.68
Analysts' Opinion
-
Consensus RatingStoke Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $23.88, Stoke Therapeutics has an estimated upside of 186.62% from its current price of $8.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing -80.07% downside risk from its current price of $8.33.
Fair Value
-
According to the consensus of 8 analysts, Stoke Therapeutics has 186.62% upside to fair value with a price target of $23.88 per share.
STOK vs. S&P 500
-
Over the past 5 trading days, Stoke Therapeutics has overperformed the S&P 500 by 2.28% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Stoke Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Stoke Therapeutics has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Stoke Therapeutics reported revenues of $22.6M.
Earnings Growth
-
Stoke Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Stoke Therapeutics reported earnings per share of -$0.18.
Enterprise value:
233.6M
EV / Invested capital:
1.02x
Price / LTM sales:
12.27x
EV / EBIT:
--
EV / Revenue:
6.39x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.68x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-34.06%
Net Income Margin (TTM):
-243.42%
Return On Equity:
-44.32%
Return On Invested Capital:
-44.32%
Operating Margin:
-60.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $12.4M | $8.8M | $36.6M | $2.8M | $22.6M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$104.4M | -$114.8M | -$101.4M | -$29.6M | -$13.7M | |
| EBITDA | -$102.8M | -$112.3M | -$99.2M | -$29M | -$13.1M | |
| Diluted EPS | -$2.60 | -$2.37 | -$1.68 | -$0.60 | -$0.18 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $293.9M | $229.2M | $244.1M | $215.3M | $232.8M | |
| Total Assets | $297.9M | $238.9M | $256.1M | $228.3M | $271.6M | |
| Current Liabilities | $11.4M | $17.1M | $31.4M | $30.8M | $40.1M | |
| Total Liabilities | $11.8M | $21.1M | $71.2M | $68.8M | $42.5M | |
| Total Equity | $286.1M | $217.8M | $184.8M | $159.6M | $229M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$31.9M | -$81.1M | -$86.9M | -$20.6M | -$23.2M | |
| Cash From Investing | -$45.9M | $105.9M | -$107.5M | $14.8M | $819K | |
| Cash From Financing | $46.4M | $53M | $131.1M | $7.3M | $568K | |
| Free Cash Flow | -$35.8M | -$82.7M | -$87.1M | -$20.9M | -$23.2M | |
STOK
Sector
Market Cap
$450.5M
$37.4M
Price % of 52-Week High
47.38%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
-21.62%
-0.75%
1-Year Price Total Return
39.07%
-38.36%
Beta (5-Year)
0.988
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$8.49
200-day SMA
Sell
Level
$12.49
Bollinger Bands (100)
Sell
Level
9.15 - 12.69
Chaikin Money Flow
Sell
Level
-12.4M
20-day SMA
Buy
Level
$8.29
Relative Strength Index (RSI14)
Sell
Level
44.29
ADX Line
Sell
Level
24.73
Williams %R
Neutral
Level
-38.843
50-day SMA
Sell
Level
$9.58
MACD (12, 26)
Sell
Level
-0.39
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
18.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.6309)
Sell
CA Score
(Annual)
Level (-0.9634)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.7944)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Stock Forecast FAQ
In the current month, STOK has received 7 Buy ratings 1 Hold ratings, and 0 Sell ratings. The STOK average analyst price target in the past 3 months is $23.88.
-
Where Will Stoke Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Stoke Therapeutics share price will rise to $23.88 per share over the next 12 months.
-
What Do Analysts Say About Stoke Therapeutics?
Analysts are divided on their view about Stoke Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Stoke Therapeutics is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Stoke Therapeutics's Price Target?
The price target for Stoke Therapeutics over the next 1-year time period is forecast to be $23.88 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is STOK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Stoke Therapeutics is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of STOK?
You can purchase shares of Stoke Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Stoke Therapeutics shares.
-
What Is The Stoke Therapeutics Share Price Today?
Stoke Therapeutics was last trading at $8.15 per share. This represents the most recent stock quote for Stoke Therapeutics. Yesterday, Stoke Therapeutics closed at $8.33 per share.
-
How To Buy Stoke Therapeutics Stock Online?
In order to purchase Stoke Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 21
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Buy
95
EXOD alert for Mar 21
Exodus Movement [EXOD] is up 1.11% over the past day.
Sell
15
FG alert for Mar 21
F&G Annuities & Life [FG] is down 4.61% over the past day.
